Two companies met our criteria from the two 10-K annual reports filed with the SEC on 24 August 2026. To qualify, a company must have filed an annual 10-K report on the target date and have a prior-year 10-K available for a direct year-over-year comparison.
SEC What Changed Methodology
Each company is scored on how similar its current annual filing text is to the prior year. Scores run from 0 to 1 — a score of 1 means the language is essentially unchanged; a lower score means more has changed. We flag three sections that carry the most disclosure signal: Business, Risk Factors, and MD&A. Recent research suggests that lower scores indicate that a company has made significant changes to their filings, these changes are often buried in the filings. If a company was to report positive news, they would likely do so in the form of a press release or statement on their website. The large changers have often underperformed in the market, while the stable-language filers have earned positive abnormal returns.
Key Takeaways
- BIO-TECHNE Corp (Medium) — Bio-Techne is signaling that merger execution and acquisition-related compliance risk are now the key issues investors should watch.
- NAPCO SECURITY TECHNOLOGIES, INC (Low) — This filing comparison does not show a material new development for NAPCO.
Ranking Table
| Rank | Company | CIK | Full Filing Similarity | Business Similarity | Risk Factors Similarity | MD&A Similarity | Most Changed Section | Assessment |
|---|---|---|---|---|---|---|---|---|
| 1 | BIO-TECHNE Corp | 842023 | 0.999 | 0.993 | 0.992 | 0.993 | Risk Factors | medium |
| 2 | NAPCO SECURITY TECHNOLOGIES, INC | 69633 | 0.997 | n/a | n/a | n/a | N/A | low |
BIO-TECHNE Corp
| Rank | 1 |
|---|---|
| Lowest similarity section | Risk Factors |
| Assessment | medium |
| SEC filings | 2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text) |
Bio-Techne’s filing now puts a pending merger front and center in its risk disclosures, including the chance the deal slips, costs more than expected, or fails altogether. The company also added a new disclosure item on foreign jurisdictions that prevent inspections, while reiterating that recent acquisitions have increased privacy and security risk tied to protected health information. Overall, the filing reads as more transaction- and compliance-sensitive than last year.
Main Changes
- The forward-looking statements section now explicitly adds "the Merger," including timing of completion, required approvals, merger-related costs, litigation or shareholder action, and the risk that the deal is not completed.
- A new Item 9C was added: "Disclosure Regarding Foreign Jurisdictions that Prevent Inspections," which was not listed in the prior filing.
- The risk factor discussion continues to emphasize healthcare, privacy, and HIPAA exposure, but now also highlights that privacy and security risk is "elevated with recent acquisitions" that use protected health information and healthcare providers for lab testing.
Watch Items
- The new merger references suggest a material corporate transaction is now a central execution and disclosure risk for the company.
- The added foreign-inspection item can signal regulatory or geopolitical exposure that may affect operations, compliance, or market access.
- The emphasis on acquisitions increasing PHI-related risk points to higher integration and compliance burden, which can raise legal and reputational downside.
Important Filing Changes
Without limiting the foregoing, we have experienced and/or may in the future experience: ● adverse impacts on customer orders and purchases and unpredictable reductions in demand for many of our products; ● constraints on the movement of our products through the supply chain, which can disrupt our ability to produce or deliver our products; ● adverse impacts on our collections of accounts receivable, including delays in collections and increases in uncollectible receivables, as well as the risk of excess or obsolete inventory; ● price increases in our raw materials and capital equipment, as well as increasing price competition in our markets; ● adverse impacts on our workforce and/or key employees; ● increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations which, in addition to increasing…
Without limiting the foregoing, we have experienced and/or may in the future experience: ● adverse impacts on customer orders and purchases and unpredictable reductions in demand for many of our products; ● constraints on the movement of our products through the supply chain, which can disrupt our ability to produce or deliver our products; ● adverse impacts on our collections of accounts receivable, including delays in collections and increases in uncollectible receivables, as well as the risk of excess or obsolete inventory; ● price increases in our raw materials and capital equipment, as well as increasing price competition in our markets; ● adverse impacts on our workforce and/or key employees; ● increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations which, in addition to increasing the risks identified above, could result in preference actions against us; and ● adverse impact to the sizes and growth rates of the markets we serve. If growth in the global economy or in any of the markets we serve slows for a significant period, if there is significant deterioration in the global economy or such markets or if improvements in the global economy do not benefit the markets we serve, our business and financial results can be adversely affected. International political, compliance and business factors, including the military conflicts and trade tensions, can negatively impact our operations and financial results. We engage in business globally, with approximately 48% of our sales revenue in fiscal 2026 coming from outside the U.S.
Changes, potential changes or uncertainties in social, political, regulatory, and economic conditions or laws and policies governing foreign trade, manufacturing, and development and investment in the territories and countries where we or our customers operate, or governing the health care system, can adversely affect our business and financial results. For example, Congress and the U.S. administration have sought to impose changes to healthcare in the United States, including government negotiation/regulation of drug prices paid by government programs. Such impacts could negatively impact certain markets we serve, resulting in an adverse impact on our sales revenue.
Changes, potential changes or uncertainties in social, political, regulatory, and economic conditions or laws and policies governing foreign trade, manufacturing, and development and investment in the territories and countries where we or our customers operate, or governing the health care system, can adversely affect our business and financial results. For example, Congress and the U.S. administration have sought to impose changes to healthcare in the U.S., including government negotiation/regulation of drug prices paid by government programs. Such impacts could negatively impact certain markets we serve, resulting in an adverse impact on our sales revenue.
This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. RECENT ACQUISITIONS A key component of the Company’s strategy is to augment internal growth at existing businesses with complementary acquisitions.
This segment also includes proteomic analytical tools, both manual and automated, that offer researchers and pharmaceutical manufacturers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications. PENDING MERGER WITH MERCK KGAA, DARMSTADT, GERMANY On June 25, 2026, the Company entered into the Agreement and Plan of Merger (the “Merger Agreement”), with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Parent”), and EMD Holdings NewCo, Inc., a Minnesota corporation and a wholly-owned subsidiary of Parent (“Merger Sub”).
NAPCO SECURITY TECHNOLOGIES, INC
| Rank | 2 |
|---|---|
| Lowest similarity section | N/A |
| Assessment | low |
| SEC filings | 2026 10-K HTML/iXBRL (SEC page, raw text) | 2025 10-K HTML/iXBRL (SEC page, raw text) |
Based on the sections provided, there is no visible year-over-year change to highlight in NAPCO Security Technologies’ 10-K. That suggests the filing is largely a repeat of prior disclosure rather than a signal of a new strategic shift or risk update.
No material section-level wording change was large enough to quote from the compared sections.
Why SEC Filing Changes Matter
Research by Cohen et al. (Lazy Prices, 2020) — using the complete history of SEC filings from 1995 to 2014 — shows that when firms make active changes to their annual disclosures, those changes convey an important signal about future operations and returns. A portfolio that shorted "changers" and bought "non-changers" earned over 22% per year in annual alpha historically. Changes to the Risk Factors section, Business description, and language referring to the executive team were especially informative. Critically, these returns accrued gradually as information was later revealed through news and earnings — not at the time of filing — suggesting many investors remain inattentive to these simple, public signals. This snapshot is a starting point for deeper investigation, not a buy or sell recommendation.
For more like this, see the full SEC What Changed archive, browse more equity research reports, or subscribe to Quantitative Research Notes for new filing-change alerts as soon as they publish.
Leave a Comment